ZEAL: Zealand Pharma A/S - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Zealand Pharma A/S

DNK:ZEAL

SummaryFactSheetFinancial
Price
kr321.20
Loss Chance
48.4%
2.81JITTA SCORE
40.38%Under Jitta Line
Jitta Ranking
Biotechnology
3 / 5
Health Care
11 / 19
Denmark
?
81 / 124
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Bavarian Nordic A/S
DNK:BAVA
3.51
kr209.40
75.29%
BioPorto A/S
DNK:BIOPOR
2.91
kr1.28
100.00%
Genmab A/S
DNK:GMAB
5.59
kr2,151.00
148.79%
H. Lundbeck A/S
DNK:HLUN A
7.40
kr40.50
5.64%
H. Lundbeck A/S
DNK:HLUN B
7.40
kr41.04
4.38%
Jitta Factors
Growth Opportunity (20)
Recent Business Performance (22)
Financial Strength (58)
Return to Shareholders (24)
Competitive Advantage (36)
Jitta Signs
Debt LevelLow Long Term Debt
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2024
Operating MarginInconsistent
Recent Business PerformanceEarning decline 47.66% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
2.81
40.38%
3.53
76.74%
4.64
69.38%
Biotechnology
3.51
75.29%
2.91
100.00%
5.59
148.79%
COMPANY DESCRIPTION
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
www.zealandpharma.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.